跳到正文
原文
Medical Xpress·· 2026-10-03精选AI 评分69

研究证实欧洲8国可行儿童1型糖尿病筛查

Study across 8 European countries demonstrates feasibility of screening children for type 1 diabetes

AI 导读

研究人员在八国开展的试点研究,共筛查140,568名儿童,结果证实了在欧洲地区开展针对早期1型糖尿病筛查的可行性,并识别出早期患者。

推荐理由

原文基于多中心真实筛查数据呈现早期1型糖尿病检出率及不同国家的实施差异。

正文
blood test
Credit: Artem Podrez from Pexels

New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), reports on pilot screening programs for type 1 diabetes in eight countries. The authors—a consortium including Dr. Peter Achenbach and professor Anette-Gabriele Ziegler from the Institute of Diabetes Research, Helmholtz Munich, Munich, Germany—say that screening should be rolled out across Europe, ideally with three testing windows: ages 2–4, 6–8 and 10–15.

Earlier research from these authors has established the existence of presymptomatic stages of T1D, stages 1 and 2—what was already known as the symptomatic stage is now stage 3.

Early detection of type 1 diabetes (T1D) is important as preventive and disease-modifying strategies are being established (with one, teplizumab, already available and others in development), and identifying individuals in the presymptomatic stage is associated with clinical benefits, including a reduced risk of diabetic ketoacidosis.

The EDENT1FI consortium is a European collaborative initiative aimed at advancing population-based screening and harmonizing early detection approaches across countries, coordinated jointly by professor Chantal Mathieu from KU Leuven, Belgium, and Ziegler.

On behalf of EDENT1FI, using a common protocol, the authors have established screening for islet autoantibodies to assess feasibility, participation rates, the prevalence of early-stage T1D, and the performance and comparability of assays across participating centers.

Sites in eight countries participated: the Czech Republic (Prague), Denmark and Sweden (Copenhagen and Öresund Region), Germany (Munich, Hanover, Dresden), Italy (Milan), Poland (Warsaw, Katowice), Portugal (Lisbon, Matosinhos, Beja) and the U.K. (Birmingham). The screening targeted children and adolescents ages 2 to 10 in Germany and 2 to 17 in other countries (due to site-specific variations in screening protocols).

Screening used capillary blood for the initial test (dried blood spots in the U.K.) and venous blood samples for confirmation. A test for a combination of three autoantibodies (GADA, IA-2A, ZnT8A) was used for initial screening.

Samples that tested positive were analyzed for four autoantibodies (GADA, IA-2A, ZnT8A, and IAA) at two central laboratories (Munich, Milan). Participants with at least two autoantibodies underwent confirmatory testing; early-stage T1D was diagnosed following confirmation.

Individuals with early-stage T1D were invited for education and metabolic staging (oral glucose tolerance testing and HbA1c). The study screened children with and without a first-degree relative with T1D—the proportion without such a relative is much higher than the proportion with one.

A total of 140,568 children and adolescents (49.2% female) participated in screening at a median age of 7.6 years, including 10,273 (7.3%) with and 127,754 (90.9%) without a first-degree family history of T1D, and 2,541 whose family history was not reported. Of those, 219 (2.13%, or around 1 in 45) with and 408 (0.32%, or 1 in 350) without a family history had early-stage T1D.

Frequencies among children without a family history ranged from 0.22% in Germany to 0.42% in the U.K. and 0.47% in Sweden and were associated with age (meaning that the prevalence of early-stage T1D was lowest among children in the age group of <4 years (0.22%) and increased in the age groups of 4 to <8 (0.31%) and 8 to <13 (0.40%)).

In Italy, where screening took place in the EASD host city of Milan, 4,507 participants with a median age of 6.5 years were screened, including 3,641 (80.8%) without a first-degree family history of T1D, of whom five (0.14%) had early-stage T1D. No cases of T1D were detected in the 167 Italian children with a first-degree relative with T1D.

In the U.K., a total of 17,409 children were screened, with a median age of 8.4 years. Among these, 59 cases were found (0.42%) among those without a first-degree relative with T1D and 67 (3.43%) among those with one.

In Sweden, a total of 7,926 children were screened, with a median age of 9.4 years. Among these, 36 cases were found (0.47%) among those without a first-degree relative with T1D and four (1.21%) among those with one.

In Germany, among 43,470 children screened, with a median age of 4.3 years, case rates were notably lower, with 90 (0.22%) in children without a first-degree relative with T1D and 35 (1.36%) in those with one.

Of the total 634 participants with early-stage T1D, 386 (61%) completed metabolic staging: 300 (78%) had stage 1, 70 (18%) stage 2 and 16 (4.1%) stage 3 T1D. Participants with early-stage T1D are included in the European pre-T1D Registry.

The authors say, "This study shows that screening principles originally developed in Germany can be successfully applied to regions with different health care systems. The EDENT1FI initiative further demonstrates that screening for early-stage T1D can be effectively implemented throughout Europe."

"The next steps are aimed at integrating screening for early-stage T1D in the general population into standard medical care. In addition to Europe, there are other screening initiatives worldwide for the early detection of T1D, including in the United States and Australia."

Italy has passed legislation to establish nationwide screening for T1D, but the government and regional health systems are continuing work to implement the law.

Provided by European Association for the Study of Diabetes

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Study across 8 European countries demonstrates feasibility of screening children for type 1 diabetes (2026, October 2) retrieved 2 October 2026 from https://medicalxpress.com/news/2026-10-european-countries-feasibility-screening-children.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com